Previous 10 | Next 10 |
2024-02-06 12:46:00 ET More on Astria TherapeuticS Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout Astria Therapeutics stock jumps on pricing of $125M underwritten offering Astria TherapeuticS GAAP EPS of -$0.63 misses by $0.14 ...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming virtual Oppenheimer...
2024-02-04 04:19:51 ET Summary Astria Therapeutics (formerly Catabasis Pharmaceuticals) acquired Quellis Biosciences and its lead program, STAR-0215, for the treatment of hereditary angioedema (HAE) in 2021. The company has successfully completed a Phase 1 study for STAR-0215, dem...
2024-01-30 10:09:22 ET More on Astria TherapeuticS Astria Therapeutics, Inc. (ATXS) Q3 2023 Earnings Call Transcript Astria Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Astria TherapeuticS GAAP EPS of -$0.63 misses by $0.14 Seeking Alpha&...
Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, tod...
2023-12-15 11:54:45 ET More on Astria TherapeuticS Astria TherapeuticS GAAP EPS of -$0.63 misses by $0.14 Astria Therapeutics prices $64 million securities offering For further details see: Astria Therapeutics files $500M mixed securities shelf
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share STAR-0215 Phase 1a results in an encore presentation at the annual World Allergy Congress on Sunday, Dec...
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and information on STAR-0215 and STAR...
2023-11-13 08:01:42 ET More on Astria TherapeuticS Astria Therapeutics: Too Much Baggage, Too Strong A Competition Astria Therapeutics prices $64 million securities offering Astria signs licensing deal with Ichnos Sciences to develop atopic dermatitis treatment ...
-- New Phase 1a Results Confirm Potential for STAR-0215 to Prevent HAE Attacks with Dosing 2 or 4 Times Per Year -- -- ALPHA-STAR Trial of STAR-0215 Initial Proof-of-Concept Data in Patients Now Expected Q1 2024 -- -- STAR-0310, Potential Best-in-Class OX40 Program for the Treatme...
News, Short Squeeze, Breakout and More Instantly...
Astria Therapeutics Inc. Company Name:
ATXS Stock Symbol:
NASDAQ Market:
Astria Therapeutics Inc. Website:
2024-06-16 18:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allerg...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Va...